Great West Life Assurance CO Morphic Holding, Inc. Transaction History

Great West Life Assurance CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$26.64 - $40.31 $100,299 - $151,767	-3,765 Reduced 22.23%	13,173 $463,000
Q4 2023 Feb 13, 2024	BUY	$19.95 - $31.0 $53,126 - $82,553	2,663 Added 18.65%	16,938 $486,000
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $15,741 - $43,851	-738 Reduced 4.92%	14,275 $327,000
Q2 2023 Aug 10, 2023	BUY	$34.33 - $62.11 $56,026 - $101,363	1,632 Added 12.2%	15,013 $867,000
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $2,002 - $3,749	-77 Reduced 0.57%	13,381 $505,000
Q4 2022 Feb 10, 2023	BUY	$24.14 - $30.37 $156,885 - $197,374	6,499 Added 93.39%	13,458 $362,000
Q3 2022 Nov 01, 2022	BUY	$22.23 - $33.37 $154,698 - $232,221	6,959 New	6,959 $196,000
Q4 2020 Feb 16, 2021	BUY	$25.66 - $34.55 $20,220 - $27,225	788 New	788 $26,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

Stay updated on Great West Life Assurance CO with notifications on news.